Inventor
LI XIAOFEN
US42 patents
⚠️ This page may combine multiple inventors who share the name “LI XIAOFEN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GILEAD SCIENCES INC
16 patentsUS10703733B2Jul 7, 2020
MCL-1 inhibitors
GILEAD SCIENCES INC12 citations93
US8697863B2Apr 15, 2014
Fused heterocyclic compounds as ion channel modulators
GILEAD SCIENCES INC13 citations93
US10988451B2Apr 27, 2021
MCL-1 inhibitors
GILEAD SCIENCES INC10 citations85
US9676760B2Jun 13, 2017
Fused heterocyclic compounds as ion channel modulators
GILEAD SCIENCES INC7 citations84
US9598435B2Mar 21, 2017
Fused heterocyclic compounds as ion channel modulators
GILEAD SCIENCES INC9 citations84
US9193694B2Nov 24, 2015
Fused heterocyclic compounds as ion channel modulators
GILEAD SCIENCES INC11 citations84
US11643400B2May 9, 2023
MCL-1 inhibitors
GILEAD SCIENCES INC4 citations74
US9403782B2Aug 2, 2016
Fused heterocyclic compounds as ion channel modulators
GILEAD SCIENCES INC4 citations73
US12162844B2Dec 10, 2024
MCL-1 inhibitors
GILEAD SCIENCES INC0 citations62
US11229638B2Jan 25, 2022
Therapeutic heterocyclic compounds
GILEAD SCIENCES INC0 citations61
US11040033B2Jun 22, 2021
Therapeutic heterocyclic compounds
GILEAD SCIENCES INC1 citations61
US9695192B2Jul 4, 2017
Fused heterocyclic compounds as ion channel modulators
GILEAD SCIENCES INC0 citations52
US9682998B2Jun 20, 2017
Fused heterocyclic compounds as ion channel modulators
GILEAD SCIENCES INC0 citations52
US11186579B2Nov 30, 2021
Therapeutic heterocyclic compounds
GILEAD SCIENCES INC0 citations50
US11098027B2Aug 24, 2021
Therapeutic heterocyclic compounds
GILEAD SCIENCES INC0 citations50
US10100058B2Oct 16, 2018
Fused heterocyclic compounds as CaM kinase inhibitors
GILEAD SCIENCES INC0 citations41
CV THERAPEUTICS INC
14 patentsUS6977300B2Dec 20, 2005
A2B adenosine receptor antagonists
CV THERAPEUTICS INC69 citations98
US6825349B2Nov 30, 2004
A2B adenosine receptor antagonists
CV THERAPEUTICS INC95 citations98
US7317017B2Jan 8, 2008
A2B adenosine receptor antagonists
CV THERAPEUTICS INC22 citations92
US7304070B2Dec 4, 2007
A2B adenosine receptor antagonists
CV THERAPEUTICS INC23 citations92
US7125993B2Oct 24, 2006
A2B adenosine receptor antagonists
CV THERAPEUTICS INC37 citations92
US7105665B2Sep 12, 2006
A2B adenosine receptor antagonists
CV THERAPEUTICS INC12 citations84
US7521554B2Apr 21, 2009
A2B adenosine receptor antagonists
CV THERAPEUTICS INC7 citations73
US7144871B2Dec 5, 2006
Partial and full agonists of A1 adenosine receptors
CV THERAPEUTICS INC5 citations73
US7514417B2Apr 7, 2009
A1 adenosine receptor agonists
CV THERAPEUTICS INC2 citations63
US7381714B2Jun 3, 2008
A1 adenosine receptor agonists
CV THERAPEUTICS INC4 citations63
US7022681B2Apr 4, 2006
Partial and full agonists of A1 adenosine receptors
CV THERAPEUTICS INC2 citations63
US7449473B2Nov 11, 2008
Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
CV THERAPEUTICS INC5 citations62
US7488720B2Feb 10, 2009
A1 adenosine receptor agonists
CV THERAPEUTICS INC1 citations52
US7696181B2Apr 13, 2010
Partial and full agonists of A1 adenosine receptors
CV THERAPEUTICS INC1 citations51
CORKEY BRITTON KENNETH
3 patentsUS8586732B2Nov 19, 2013
Fused heterocyclic compounds as ion channel modulators
CORKEY BRITTON KENNETH29 citations91
US9115096B2Aug 25, 2015
Fused heterocyclic compounds as ion channel modulators
CORKEY BRITTON KENNETH5 citations83
US8962610B2Feb 24, 2015
Fused heterocyclic compounds as ion channel modulators
CORKEY BRITTON KENNETH6 citations83
CORKEY BRITTON
2 patentsGILEAD PALO ALTO INC
2 patentsUNIV SHANGHAI JIAOTONG
2 patentsUS12412680B2Sep 9, 2025
Composite superconducting tape, combination and preparation method thereof, and defect bypassing and joint connection method
UNIV SHANGHAI JIAOTONG0 citations52
US11871683B2Jan 9, 2024
Charging and field supplement circuit for superconducting magnets based on pulsed current
UNIV SHANGHAI JIAOTONG0 citations44